Bezafibrate for the treatment of hypertriglyceridemia in HIV1-infected patients on highly active antiretroviral therapy

Brazilian Journal of Infectious Diseases

Volumn 10, Issue 3, 2006, Pages 159-164

  Geraix, Juliana ^a   de Souza, Micheli Evangelista ^a   Delatim, Francieli Cristina ^a   Pereira, Paulo Câmara Marques ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Bezafibrate; HAART; HIV; Hypertriglyceridemia

Indexed keywords

ANTIRETROVIRUS AGENT; BEZAFIBRATE; CD4 ANTIGEN; CD8 ANTIGEN; CEDURA RETARD; CREATINE KINASE; LIVER ENZYME; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FAMILY HISTORY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MALE; NONHUMAN; OBESITY; SITTING; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; ANTILIPEMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BEZAFIBRATE; CD4-CD8 RATIO; FEMALE; HIV INFECTIONS; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33749079204     PISSN: 14138670     EISSN: 14138670     Source Type: Journal    
DOI: 10.1590/S1413-86702006000300001     Document Type: Article

References (52)

1. Ferrini M.T., Pasternak J., Waitzberg D.L. Síndrome da Imunodeficiência Adiquirida (AIDS). In: Waitzberg D.L. Nutrição oral, enteral e parenteral na prática clínica. 3. ed. São Paulo: Atheneu, 2000.
2. Patella Jr F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N EngI J Med 1998;338(13):853-60.
3. Martinez R., Casamitjana I., Gatell J.M. Protease inhibitor - associated hyperinsulinaemia. AIDS 1998; 12(15):2077-9.
4. Sullivan A.K., Nelson M.R. Marked hyperlipidaemia on ritonavir therapy. AIDS 1997; 11(7); 93 8-9.
5. Viraben R., Christian A. Indinavir - Associated Lipodystrophy. AIDS 1998;12:F13-39.
6. Carr A., Samaras K., Chisholm D.J., Cooper D.A. Pathogenesis of HIV-1 - protease inhibitor - associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance. Lancet 1998 b;20; 351(9119):1881-3.
7. Carr A., Samaras K., Burton S., Law M., Freund J., Chisholm D.J. et al. A syndrome of peripheral lipodistrophy, hyperlipidaemia and insulin resistence in patients receiving HIV protease inhibitors. AIDS 1998a; 12:F51-8.
8. Grunfeld C., Kotler D.P., Shigenaga J.K., et al. Circulating interferon-a levels and hypertriglyderidemia in the Acquired Immunodeficiency Syndrome. Am J Med 1991;90:154-62.
9. Caar A., Samaras K., Burton S., et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistence in patients HIV receiving protease inhibitors. AIDS 1998a; 12(7):F51-58.
10. Grunfield C., Kotler D.P., Hamadeh R., et al. Hypertriglyceridemia in the Acquired Immunodeficiency Syndrome. Am J Med 1989;86:27-31.
11. Kotler D.P. Update on lipid abnormalities and cardiovascular complications in HIV infection. In: Program and abstracts: XXXVIII Satellite Symposium ICAAC (San Diego), San Diego, 1998.
12. Kotler D.P., Tierney A.R., Wang J., Pierson Jr R.N. Magnitude of body- cell-mass depletion and the timing of death from wasting in aids. Am J Clin Nutr 1989;50:444-7.
13. Frick M.H., Elo O., Haapa K., et al. Helsinki heart study: primary prevention trial with genifibrozil in middle-age men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary artery disease. N Engl J Med 1987;317(20):1237-45.
14. Carr A., Samaras K., Thorisdottir A., et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-9.
15. Gallet B., Pulik M., Genet P., et al. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998;351:1958-60.
16. Henry K., Melore H., Huebsch J., et al. Severe premature coronary artery disease with protease inhibitor [letter]. Lancet 1998;351(9112):1328.
17. Juette A., Salzeberg B., Franzen C., et al. Increase morbidity from severe coronary heart disease in HIV-patients receiving protease inhibitor. In: Program and abstracts: VI Conference on Retroviruses and Opportunistic Infections (Chicago), Chicago, 1999.
18. Dong B.J., Gruta C.I., Legg J.J. Diabetes and use of protease inhibitor. In: Program and abstracts: XII World AIDS Conference (Geneva), Geneva, 1998.
19. Mishriki Y.Y. Baffling case of bulging belly. Protease punch. Postgrad Med 1998; 104(3):45-6.
20. Madge S., Kinloch-De Loes S., Tyrer M., Johnson M.A. Lipodystrophy syndrome (LS) in patients on reverse transcriptase inhibitors. In: Program and abstracts: VI Conference on Retroviruses and Opportunistic Infections (Chicago), Chicago, 1999.
21. Gervasoni C., Ridolfo A.L., Trifiro G., et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999; 13(4):465-71.
22. Kotler D.P, Ellen S., Engelson E.D. Surmnary report - Third International Conference on Nutrition in HIV Infection - MEDSCAP HIV/AIDS 5 (3), 1999.
23. Galli M., Ridolfo A.L., Gervasoni C. Cardivascular disease risk factors in HIV-infected patients in the HAART Era. Ann NY Acad Sci 2001;946:200-13.
24. III Diretrizes Brasileiras Sobre Dislipidemias e Diretriz de Prevenção da Aterosclerose do Departamento de Atersclerose da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol 2001;77(S III).
25. Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of adult aids clinical trial group cardiovascular disease focus group. Clin Infect Dis 2000;31:1216-24.
26. National Cholesterol Education Program. Summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;10:299-313.
27. Henry K., Huebesch J., Hermundson J., Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998;352:1031-2.
28. Santos D.S. Abordagem prática do manuseio das dislipidemias associadas à infecção pelo HIV e seu tratamento. BJID 2004;8:22-36.
29. Ericsson C.G, Hamsten A., Nilsson J., Grip L., Svane B., de Faire U. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996;347:849-53.
30. World Health Organization. Obesity: preventing and managing the global epidemic of obesity. In: Report of the WHO consultation of obesity. Geneva, 3-5 june, 1997.
31. Calza L., Manfredi R., Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003;14:851-9.
32. Stein J.H. Managing cardiovascular risk in patients with HIV infection. J Acquir Immune Defic Syndr 2005;38:115-23.
33. Sanjay N.P., Dravid A., Naik E., et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active therapy regimens in Western India. J Acquir Immune Defic Syndr 2005;39:199-202.
34. Kamin D.S., Grinspoon S.K. Cardiovascular disease in HIV-positive patients. AIDS 2005;19:641-52.
35. Dolan S.E., Hadigan C., Killilea K.M., et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2005;39:44-54.
36. Achutt A. Epidemiologia das doenças cardiovasculares (DCV): Dados do Brasil. Curso de Reciclagem em Cardiologia da Sociedade de Cardiologia do RS/SBC, 2003. www.cardiol.com.br
37. Szwarcwald C.L., Bastos F.I., Andrade C.L.T., Castilho E.A. Aids: o mapa ecológico do Brasil 1982-1994. In: A epidemia da aids no Brasil: situação e tendências. Brasilia: Ministério da Saúde. Coordenação Nacional de DST e Aids. Ministério da Saúde Brasília 1997; p.27-44.
38. Boletim epidemiológico. AIDS ANO XVII no 01. 01 a 52 Semanas epidemiológicas janeiro a dezembro de 2003. Available from: http://www.Aids.gov.br/final/dados/bol_aids1.htm
39. Wilcox J.K., Catignani G.L., Lazarus S. Tomatoes and cardiovascular health. Crit Rev Food Sci Nutr 2003;43(1):1-18.
40. Behrens G, Dejam A., Schmidt H., et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999;13:F63-70.
41. Schmidt H.H., Behrens G., Genschel J., et al. Lipid evaluation in HIV-1-positive patients treated with protease inhibitors. Antivir Ther 1999;4:163-70.
42. Carr A., Cooper D. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-30.
43. Penzak S.R., Chuck S.K. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis 2000;32:111-23.
44. Brewer H.B. Hypertriglyceridemia: changes in the plasma lioproteins associated with an increased risk of cardiovascular disease. Am J Cardiol 1999;83:3F-12.
45. Calza L., Manfredi R., Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 2003;17:851-9.
46. Manfredi R. Management of dyslipidemia in patients with HIV disease. Clin Microbiol Infect 2000;6:579-84.
47. Saint-Marc T., Partisani M., Poizot-Martin I., et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14:37-49.
48. Moyle G.J., Baldwin C. Lipid elevations during non-nucleoside RTI (NNRTI) therapy: a cross-sectional analysis. Antivir Ther 1999;4(Suppl 2):54.
49. Sullivan A.K., Feher M.D., Nelson M.R., Gazzard B.G. Marked hypertriglyceridemia associated with ritonavir therapy. AIDS 1998;12:1393-4.
50. Palacios R., Santos J., González M., Ruiz J. Letters to the editor: Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy. J AIDS 2002;31:251-2.
51. Dresser G.K., Spence J.D., Bailey D.G. Pharmacokinetic-pharmacodynamic consequences and clinic relevance of cytochrome p450 3A4 inhibition. Clin Pharmacokinet 2000;38:41-57.
52. Mastroianni C.M., d'Ettorre G., Forcina G., et al. Rhabdomyolisis after cerivatatin-gemfibrozil therapy in an HIV-infected patient with protease inhibitor-related hyperlipidaemia. AIDS 2001;15:820-1.